WallStreetZenWallStreetZen

NASDAQ: ALLO
Allogene Therapeutics Inc Stock Ownership - Who owns Allogene Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Allogene Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Deborah M. MessemerDirector2024-12-099,136$2.18
$19.92kSell
Franz B. HumerDirector2024-12-059,221$2.16
$19.92kSell
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER2024-10-2136,404$2.84
$103.39kSell
Earl Martin DouglasSVP General Counsel2024-08-2128,310$2.79
$78.84kSell
Deborah M. MessemerDirector2024-06-1818,641$2.28
$42.48kSell
Franz B. HumerDirector2024-05-3011,200$2.34
$26.19kSell
Arie BelldegrunDirector2024-05-161,724,137$2.90
$5.00MBuy
Arie BelldegrunDirector2024-05-16344,828$2.90
$1.00MBuy
David D. ChangPresident and CEO2024-05-16344,828$2.90
$1.00MBuy
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER2024-05-16344,828$2.90
$1.00MBuy

1 of 2

ALLO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALLO insiders and whales buy or sell their stock.

ALLO Shareholders

What type of owners hold Allogene Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fmr LLC14.32%30,026,956$58.55MInstitution
Pfizer Inc10.51%22,032,040$42.96MInsider
Tpg GP A LLC8.93%18,716,306$36.50MInstitution
Tpg Group Holdings Sbs Advisors Inc8.93%18,716,306$36.50MInsider
Tpg GP A LLC8.93%18,716,306$36.50MInsider
Blackrock Inc8.48%17,772,745$34.66MInstitution
Blackrock Inc 18.48%17,772,745$34.66MInstitution
Vanguard Group Inc3.97%8,327,699$16.24MInstitution
State Street Corp3.34%7,013,083$13.68MInstitution
Capital World Investors3.29%6,896,552$13.45MInstitution

1 of 3

ALLO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALLO67.93%32.07%Net BuyingNet Selling
MBX34.38%65.62%Net Buying
KOD66.45%33.55%Net Selling
ZVRA54.26%22.69%Net Buying
AKBA27.24%8.73%Net Selling
View Top Biotech Stocks

Allogene Therapeutics Stock Ownership FAQ

Who owns Allogene Therapeutics?

Allogene Therapeutics (NASDAQ: ALLO) is owned by 78.40% institutional shareholders, 37.02% Allogene Therapeutics insiders, and 0.00% retail investors. Pfizer Inc is the largest individual Allogene Therapeutics shareholder, owning 22.03M shares representing 10.51% of the company. Pfizer Inc's Allogene Therapeutics shares are currently valued at $42.30M.

If you're new to stock investing, here's how to buy Allogene Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.